AIM ImmunoTech Inc. (AIM) Social Stream



AIM ImmunoTech Inc. (AIM): $0.78

0.00 (0.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AIM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 458

in industry

Featured Post From StockTwits About AIM

$AIM interesting that they are doing 5 doses (potentially 6 if they add a booster but CRO doesnt think they will need it which must be based on their review of the P1 data) in the human challenge study instead of the 7 doses they did in the P1 intranasal study. Also no mention of different dosage strengths in the human challenge study. So in the P1 Intranasal Study they must have identified the optimal dosage strength and number of doses to generate the best response. Seeing this protocol leads me to continue to believe the P1 data is positive and that they have all the data and we should have it soon.
beaufordb, published August 17, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4804 seconds.